#1 Clinical Trials Search in Europe

Levofloxacin Hemihydrate

This article explores the use of Levofloxacin Hemihydrate, an antibiotic medication, in clinical trials. We’ll focus on two specific studies: one investigating its effectiveness in treating Pseudomonas aeruginosa bacteremia, and another examining its pulmonary pharmacokinetics in patients with chronic obstructive pulmonary disease (COPD) or cystic fibrosis (CF). These trials aim to improve our understanding of Levofloxacin’s efficacy and optimal dosing strategies in different medical conditions.

Table of Contents

What is Levofloxacin Hemihydrate?

Levofloxacin Hemihydrate is an antibiotic medication belonging to the fluoroquinolone class of drugs[1]. It is a powerful broad-spectrum antibiotic used to treat various bacterial infections. The term “hemihydrate” refers to the chemical structure of the drug, which contains half a molecule of water for each molecule of levofloxacin.

Medical Uses

Levofloxacin is prescribed to treat a wide range of bacterial infections, including:

  • Respiratory tract infections: Such as pneumonia and chronic obstructive pulmonary disease (COPD) exacerbations[2]
  • Urinary tract infections
  • Skin and soft tissue infections
  • Bacterial sinusitis
  • Bloodstream infections (bacteremia): Particularly those caused by Pseudomonas aeruginosa, a type of bacteria that can cause severe infections[1]

It is particularly effective against gram-negative bacteria, but also works on some gram-positive bacteria.

Administration

Levofloxacin Hemihydrate is available in different forms:

  • Oral tablets: Usually film-coated tablets of 500 mg strength[1]
  • Intravenous (IV) solution: Typically a 5 mg/ml solution for infusion[2]

The route of administration depends on the severity of the infection and the patient’s condition. Oral tablets are often prescribed for less severe infections or for continuing treatment after initial IV therapy.

Dosage

The dosage of Levofloxacin Hemihydrate varies depending on the type and severity of the infection being treated. However, some general guidelines include:

  • For oral tablets: The typical daily dose is 500 mg to 1 gram[1]
  • For IV solution: The maximum daily dose is usually 1 gram[2]

The duration of treatment can range from 7 to 14 days, depending on the infection type and response to treatment[1]. Always follow your doctor’s instructions regarding dosage and duration of treatment.

Current Clinical Trials

Levofloxacin Hemihydrate is currently being studied in several clinical trials:

  1. A trial comparing 7-day versus 14-day antibiotic treatment for Pseudomonas aeruginosa bacteremia (blood infection). This study aims to determine if a shorter treatment duration (7 days) is as effective as the standard 14-day treatment, potentially reducing antibiotic exposure and side effects[1].

  2. An exploratory pharmacokinetic study examining how Levofloxacin concentrates in the lungs of patients with chronic obstructive pulmonary disease (COPD) or cystic fibrosis (CF). This study compares different methods of measuring antibiotic levels in the lungs, which could help optimize dosing for respiratory infections[2].

These studies aim to improve our understanding of how to use Levofloxacin most effectively and safely in different patient populations.

Potential Side Effects

Like all medications, Levofloxacin Hemihydrate can cause side effects. Common side effects may include:

  • Nausea and diarrhea
  • Headache
  • Dizziness
  • Insomnia

More serious side effects, although rare, can include tendon rupture, nerve damage, and severe allergic reactions. If you experience any unusual symptoms while taking Levofloxacin, contact your healthcare provider immediately.

Precautions and Contraindications

Levofloxacin should be used with caution in certain populations:

  • Patients with a history of tendon disorders
  • Elderly patients
  • Patients with kidney problems
  • Patients with a history of seizures

It is contraindicated in patients with known allergy to Levofloxacin or other quinolone antibiotics. Pregnant and breastfeeding women should consult their doctor before using this medication.

Always inform your healthcare provider about all medications you’re taking, as Levofloxacin can interact with certain drugs.

Aspect Details
Drug Name Levofloxacin Hemihydrate
Drug Class Fluoroquinolone antibiotic
Administration Routes Oral (film-coated tablets), Intravenous (solution for infusion)
Conditions Studied Pseudomonas aeruginosa bacteremia, COPD, Cystic Fibrosis
Main Objectives Efficacy in treating bacteremia, Pulmonary pharmacokinetics
Key Measurements Antibiotic concentrations in epithelial lining fluid, tissue biopsy, and microdialysis
Patient Populations Adults with P. aeruginosa bacteremia, COPD, or CF
Treatment Duration 7-14 days (bacteremia study), Single dose (pharmacokinetic study)

FAQ

  • What is Levofloxacin Hemihydrate? Levofloxacin Hemihydrate is an antibiotic medication belonging to the fluoroquinolone class. It is used to treat various bacterial infections, including respiratory tract infections and certain types of bacteremia (blood infections).
  • What conditions are being studied in these clinical trials using Levofloxacin? The clinical trials are studying Levofloxacin's use in treating Pseudomonas aeruginosa bacteremia and examining its pulmonary pharmacokinetics in patients with chronic obstructive pulmonary disease (COPD) or cystic fibrosis (CF).
  • How is Levofloxacin administered in these trials? In these trials, Levofloxacin is administered either orally as film-coated tablets or intravenously as a solution for infusion, depending on the specific study and patient needs.
  • What is the purpose of studying pulmonary pharmacokinetics of Levofloxacin? Studying pulmonary pharmacokinetics helps researchers understand how Levofloxacin is distributed and behaves in the lungs of patients with COPD or CF. This information can help optimize dosing strategies for respiratory infections in these patient populations.
  • Are there any specific exclusion criteria for patients in these trials? Yes, some exclusion criteria include known allergies to the study drugs, severe renal or liver disease, and inability to give informed consent. For the bacteremia study, there are additional exclusions such as polymicrobial bacteremia and certain immunocompromised conditions.

Ongoing Clinical Trials on Levofloxacin Hemihydrate

  • Study of Piperacillin/Tazobactam and Levofloxacin for Patients with COPD or Cystic Fibrosis

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria

  • Study on the Effectiveness and Safety of 7 vs. 14 Days of Antibiotic Treatment with Meropenem for Patients with Pseudomonas Aeruginosa Blood Infection

    Recruiting

    1 1 1 1
    Investigated drugs:
    Spain

Glossary

  • Levofloxacin Hemihydrate: An antibiotic medication belonging to the fluoroquinolone class, used to treat various bacterial infections.
  • Bacteremia: The presence of bacteria in the bloodstream, which can lead to serious infections throughout the body.
  • Pseudomonas aeruginosa: A type of bacteria that can cause severe infections, particularly in people with weakened immune systems.
  • Chronic Obstructive Pulmonary Disease (COPD): A group of lung diseases that cause airflow blockage and breathing-related problems, including emphysema and chronic bronchitis.
  • Cystic Fibrosis (CF): An inherited disorder that causes thick, sticky mucus to build up in the lungs and other organs.
  • Pharmacokinetics: The study of how drugs move through the body, including their absorption, distribution, metabolism, and excretion.
  • Epithelial Lining Fluid: A thin layer of fluid that covers the surface of the lungs' air sacs, important for studying drug concentrations in the lungs.
  • Microdialysis: A technique used to sample and measure drug concentrations in various tissues of the body.
  • Film-coated Tablet: A type of oral medication where the tablet is coated with a thin layer to make it easier to swallow or to control its release in the body.
  • Solution for Infusion: A liquid medication that is administered directly into the bloodstream through a vein.

References

  1. http://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-7-vs-14-days-of-antibiotic-treatment-with-meropenem-for-patients-with-pseudomonas-aeruginosa-blood-infection/
  2. http://clinicaltrials.eu/?post_type=trial&p=91382